A Comprehensive Platform for Low-cost Screening and Image-guided Photodynamic Therapy (PDT) Treatment of Pre-malignant and Malignant Oral Lesions in Low-resource Setting

The primary goal of this study is to see if photodynamic therapy (PDT) is effective for treatment of lesions in the oral cavity which have high risk of becoming oral cancer. PDT treatment uses a drug, called a photosensitizer, which makes the diseased cells become light-sensitive such that they are destroyed when laser light is delivered to the target lesion. In this study a new handheld device, called SITOS (a "Screen, Image and Treat Optical System), is used. The ability of this device to simultaneously visualize the inside of the mouth and deliver laser light to the target site will be evaluated. The main questions this study seeks to answer are:
* Can this treatment completely cure oral potentially malignant lesions (OPML) without need for surgery?
* Do lesions recur after PDT treatment?
* Is the SITOS device easy to use for the doctor and comfortable for the patient, both as an oral imaging device and as a treatment device?

开始日期2025-05-01

申办/合作机构

University of Massachusetts Boston

[+4]

NCT06777511

/ Not yet recruitingN/AIIT

Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients

This will be a prospective observational trial enrolling 20 patients with osseointegrated prostheses. Participants will be recruited from the orthopaedic outpatient clinic at Walter Reed National Military Medical Center in Bethesda, MD.
All eligible consenting patients will undergo daily stoma management per standard of care.
Patients will integrate antimicrobial photodynamic therapy into their stoma management program. The first treatment will take place in the orthopaedic clinic. All others will take place at home. Topical 5-ALA will be applied to the metal at the penetration site. After 2 hours, the light delivery device will be utilized and light will be administered for 15 minutes.
Data collection: After obtaining informed consent, study personnel will record injury-specific variables, surgery-specific variables, other variables related to their hospital course, demographic variables as well as comorbidities on the study case report forms (CRFs). They will obtain this information directly from the participant, from the participant's medical record, and the participant's treating orthopaedic surgeon or other health care providers. Baseline data collection points include participant characteristics and amputation details such as age, sex, comorbidities, highest education level achieved, social support, initial reason for amputation, type of amputation and all surgical dates. Study participants will be followed at 1 and 2 weeks after initiation of PDT treatment. To ensure research participant safety, serious adverse events (SAEs) will be documented and promptly submitted to the local IRB as per the required reporting processes.
Follow-up: Study participants will be followed at 1 week and 2 weeks.

开始日期2025-03-01

申办/合作机构

Dartmouth-Hitchcock Medical Center

[+1]

NCT06665724

/ Recruiting临床1期

A Phase 1 Single Center Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy

This trial is designed to evaluate safety and explore possible efficacy of 5-aminolevulinic acid hydrochloride (5-ALA HCl, Gliolan®) with CV01 delivery of ultrasound for sonodynamic therapy in patients with newly diagnosed high-grade glioma prior to resection and standard adjuvant therapy.
The study will accrue 10 evaluable high-grade glioma patients. Patients who qualify will receive sonodynamic therapy (5 ALA combined with CV01-delivered sonication) 2 to 5 days prior to standard resection, with one study magnetic resonance imaging being performed between sonodynamic therapy and resection. Resection will be followed by standard radio-/chemotherapy. All patients will be followed up in-study for toxicities and adverse events for 28 days.

开始日期2025-01-27

申办/合作机构

Universität Leipzig

[+1]

100 项与盐酸氨酮戊酸相关的临床结果

登录后查看更多信息

100 项与盐酸氨酮戊酸相关的转化医学

登录后查看更多信息

100 项与盐酸氨酮戊酸相关的专利（医药）

登录后查看更多信息

10,785

项与盐酸氨酮戊酸相关的文献（医药）

2025-07-01·JOURNAL OF COLLOID AND INTERFACE SCIENCE

H2O2/O2 Self-Supplied Nanoplateform for amplifying oxidative stress to Accelerate Photodynamic/Chemodynamic therapy Cycles

Article

作者: Li, Yong ; Xi, Jianying ; Lv, Longhao ; Liu, Fangfang ; Liu, Jinliang ; Tang, Zhengshuai

Photodynamic (PDT) and chemodynamic therapies (CDT) relying on reactive oxygen species-mediated treatments mainly face various challenges of hypoxia, endogenous hydrogen peroxide (H₂O₂) deficiency, and glutathione (GSH) overexpression in the tumor microenvironment. Herein, we propose a novel strategy using a core-shell structured nanocomposite, UCNP@mSiO₂@5-ALA-CaO₂-Cu(UA@CC). The strategy centers on upconverting NPs and then utilizes mesoporous silica loaded with 5-aminolevulinic acid (5-ALA) to maximize the enrichment of protoporphyrin IX (Pph IX), an intra-tumor photosensitizer. Then in the acidic tumor microenvironment (TME), CaO₂ in the outer layer reacts with H₂O to form O₂, H₂O₂ and Ca²⁺, and the released H₂O₂ serves as an auxiliary "fuel" to induce acceleration of the Fenton-like (Cu²⁺) reaction and inactivation of the antioxidant GSH enzyme, thus enhancing the tumor cells' Catalysis. Furthermore, under the excitation of a 980 nm laser, 5-ALA-mediated PDT and Cu⁺-based CDT were initiated. Through interconnected processes of Ca²⁺ overload, self-supply of H₂O₂/O₂, and enhanced GSH depletion, an accelerated cycling strategy for combined PDT/CDT therapy was established, resulting in amplified oxidative stress and anti-tumor capabilities, which was validated in cancer cells and melanoma mouse models.

2025-06-01·Photodiagnosis and Photodynamic Therapy

Photodynamic therapy combined with curettage for actinic keratosis on the face and scalp: An efficient treatment for field cancerization of the skin

Article

作者: Zhang, Yuanjing ; Wang, Tian ; Lu, Wenna ; Zhang, Chi ; Chang, Ruixue

BACKGROUND:

Actinic keratosis (AK) frequently manifests as multiple regional lesions on the exposed areas of the face and scalp. The simultaneous treatment of extensive lesions with varying degrees poses a significant challenge.

OBJECTIVE:

This study evaluated the efficacy and patient satisfaction of 5-aminolevulinic acid (5-ALA) photodynamic therapy (PDT) combined with curettage in managing extensive AK on the face and scalp.

METHODS:

A retrospective analysis was conducted on patients with AK on the face and scalp treated at the dermatology department of a large hospital in a central Chinese city from 2020 to 2024. Each patient was histopathologically confirmed, exhibited a large lesion area exceeding 10 cm², and demonstrated evident field cancerization. All patients underwent curettage followed by 5-ALA PDT. During a 6-month follow-up, patient self-assessment and physician evaluations were conducted to systematically assess the treatment's efficacy, satisfaction, and adverse reactions.

RESULTS:

Fifty-six patients (38 females, 18 males) with a mean age of 76.26±9.16 years were included. Significant improvement in skin was observed, with the lesion count decreasing from 12.33±9.09 pretreatment to 1.98±1.50 post-treatment. Pain scores (VAS) decreased from 2.89±2.20 to 0.75±1.03, pruritus scores (NAS) from 2.46±0.95 to 0.51±0.73, and dermatology life quality index (DLQI) scores from 9.12±4.46 to 2.59±2.17. The primary adverse effect was pain during PDT.

CONCLUSION:

Curettage combined with 5-ALA PDT is an efficacious, safe, and efficient treatment for field cancerization of extensive AK on the face and scalp, warranting its promotion in clinical practice.

2025-06-01·Photodiagnosis and Photodynamic Therapy

Application of surgical management combined with photodynamic therapy in the treatment of nontuberculous mycobacterial infections after cosmetic surgery

Article

作者: Li, Xinying ; Yang, Yunchuan ; Wang, Hailin ; Liu, Menggang ; Kou, Huiling

BACKGROUND:

In recent years, the number of patients with nontuberculous mycobacteria (NTM) infections caused by invasive procedures such as cosmetic surgery has been increasing. However, treating NTM infections presents significant challenges, with no standardized diagnostic or treatment guidelines currently available.

METHODS:

PDT was performed using topical 20% ALA (10 mg/session) applied to the wound periphery (2 cm margin), followed by 3-hour occlusion and 635 nm laser irradiation (120 J/cm²; XD-635AB). Exposure durations were adjusted dynamically (20-40 minutes) based on real-time pain tolerance. Weekly sessions were administered until wound resolution. Pain severity (FEPS) was managed via a tiered protocol: ice/NSAIDs for scores 2-4 and opioids for scores >4. PDT was performed using 20% 5-ALA activated by a 635 nm laser with a light dose of 120 J/cm².

RESULTS:

All ten patients achieved clinical cure, with a notable reduction in the duration of therapy. All patients were followed for over six months without recurrence of infection. Post-PDT pain was universally in all patients, with FEPS scores ranging from 2 to 7, and managed effectively by the final treatment. Transient adverse events included erythema (n=10) and pruritus (n=2), resolving spontaneously within 48 hours. No chronic complications were observed.

CONCLUSION:

The combination of surgical intervention and PDT, along with appropriate antibiotic therapy, is a safe and effective approach for treating skin and soft tissue NTM infections after cosmetic surgery.

113

项与盐酸氨酮戊酸相关的新闻（医药）

2025-03-18

·GlobeNewswire-Health Care

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

First US Phase 3 study of Photodynamic Therapy (PDT) to include neck, trunk and extremitiesProtocol involves one or two PDT treatments using 1-3 tubes of Ameluz® or vehicle gel over a surface area of up to 240 cm2Treatment phase expected to be complete by Q3 2025 WOBURN, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the enrollment of the final patient in its Phase 3 clinical trial evaluating Ameluz® (aminolevulinic acid hydrochloride) for the treatment of mild to moderate actinic keratoses (AKs) on the extremities, neck and trunk. Actinic keratosis is a common skin condition found on sun-exposed areas of the body, and if left untreated, may progress to squamous cell carcinoma. Expanding field treatment options for AKs beyond the face and scalp would address a critical unmet need in dermatology. This trial is a multicenter, randomized, double-blind study comparing Ameluz® with vehicle in the field-directed treatment of actinic keratoses (AK) located on the extremities, neck and trunk with PDT using a RhodoLED lamp (BF-RhodoLED® XL or BF-RhodoLED®). It is designed to assess the safety and efficacy of Ameluz® PDT following the application of 1-3 tubes of product over a surface area (continuous or in patches) of approximately 80, 160 or 240cm2. Patients receive one PDT treatment with either Ameluz® or vehicle gel, and a second one at 12 weeks if at least one AK lesion remains. They are then followed up for approximately one year after the last PDT treatment. The study enrolled 172 patients who received either Ameluz® or vehicle gel in a ratio of 4:1. “We are thrilled to reach this pivotal stage in our clinical program,” said Dr. Hermann Luebbert, CEO and Chairman of Biofrontera Inc. “The successful enrollment of our last patient brings us one step closer to potentially offering an effective treatment option for patients with actinic keratoses on the extremities, neck and trunk. It marks a significant step in expanding the indications for Ameluz® and further demonstrates our commitment to the development of PDT.” Dr. Nathalie Zeitouni, Mohs surgeon and principal investigator at Medical Dermatology Specialists, Professor of Dermatology at the University of Arizona COM Phoenix, discussed the potential impact of the study. “Ameluz® PDT has already proven to be a valuable option for the treatment of AKs on the face and scalp. We see many patients who have these lesions on other areas of the body, and the possibility of expanding the use of Ameluz® to treat those areas is promising for both physicians and for our patients. I look forward to seeing the results of this study." With enrollment complete, Biofrontera anticipates finishing the treatment phase of the study by September, 2025 and the follow-up phase by Q2 2026. Pending positive outcomes, the company plans to submit a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) in the second half of 2026. About Actinic Keratosis AK is the most common pre-cancerous skin lesion caused by chronic sun exposure that may, if left untreated, develop into life-threatening skin cancer called squamous cell carcinoma. AKs typically appear on sun-exposed areas such as the face, bald scalp, arms or the back of the hands. In 2020, approximately 58 million people in the US were affected by AK and 13 million AK treatments were performed.3 About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X. Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to the clinical development strategy for Ameluz®, ongoing clinical trials and the future impact of such trials on the market for Ameluz®, statements relating to Biofrontera's commercial opportunities and the commercial success of its licensed products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of any extraordinary external events; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® and/or RhodoLED® XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz in combination with BF- RhodoLED® and/or RhodoLED® XL is consistent with the Company’s expectations; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), which can be obtained on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Contact:Investor RelationsAndrew Barwicki1-516-662-9461ir@bfri.com

临床3期临床结果

2025-02-25

·PRNewswire

Alpheus Medical Publishes Promising Early Clinical Results of Sonodynamic Therapy for the Treatment of Newly Diagnosed Glioblastomas

CHANHASSEN, Minn., Feb. 25, 2025 /PRNewswire/ -- Alpheus Medical, Inc., a private, clinical-stage oncology company pioneering sonodynamic therapy (SDT) for the treatment of solid body cancers, today announced the publication of a study in the Journal of Neuro-Oncology showcasing its proprietary SDT treatment in three patients with newly diagnosed glioblastomas that were not candidates for gross total tumor resection. The study reported no adverse effects with an immediate positive imaging and histopathological response indicating cancer cell death, with no impact on healthy brain tissue, after a single dose of SDT. The Company shared that it expects to begin a randomized control trial in patients with newly diagnosed glioblastoma later this year. Continue Reading "The early clinical results are very encouraging for advancing treatment options in patients with newly diagnosed glioblastoma, a disease with few effective therapies," commented Walter Stummer, Professor and Director of the Department of Neurosurgery of the University Hospital Münster, Germany, and the senior author of the study. "Sonodynamic therapy's ability to selectively induce immediate tumor cell death while sparing healthy brain tissue is unprecedented. Additionally, its diffuse nature allows treatment across the entire hemisphere, including the peripheral invasive zone and beyond, a major challenge in neuro-oncology. These factors suggest that SDT could be a significant breakthrough in glioblastoma treatment." "SDT's ability to selectively induce immediate tumor cell death while sparing healthy brain tissue is unprecedented." Post this Alpheus Medical's novel SDT therapy delivers low-intensity diffuse ultrasound (LIDU™) combined with oral 5-aminolevulinic acid (5-ALA) to selectively target and destroy cancer cells across the entire brain hemisphere. This non-invasive treatment, performed without the need for imaging or sedation, offers a revolutionary new approach to cancer care in an outpatient setting. This news builds on the previously presented first-in-human positive results from the Company's Phase 1/2 trial in recurrent, high-grade glioma patients, a population with very short survival expectancy. The open-label, multicenter study demonstrated a greater than twofold increase in median overall survival and a threefold improvement in progression-free survival for patients treated with SDT, underscoring its potential as a transformative therapy for this aggressive disease. About Alpheus Medical, Inc. Alpheus Medical is a private, clinical-stage oncology company revolutionizing the treatment of solid body cancers with its pioneering sonodynamic therapy (SDT) platform that combines Low-Intensity Diffuse Ultrasound (LIDUTM) with the sensitizing agent, oral 5-aminolevulinic acid (5-ALA). The company's proprietary, non-invasive technology is designed to selectively target and destroy cancer cells in the brain while preserving healthy tissue. Alpheus Medical collaborates with global neuro-oncology leaders and receives support from Brightedge, the impact investment and innovation arm of the American Cancer Society, and the Brain Tumor Investment Fund, a subsidiary of the National Brain Tumor Society. Learn more at . SOURCE Alpheus Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床结果ASCO会议

2025-01-08

·GlobeNewswire-Health Care

Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Last patient completed 1 year follow-up of study ALA-BCC-CT013 in December 2024.Data from follow-up will be included in FDA submission, expected in Q3 2025.Biofrontera announced highly statistically significant results for all primary and secondary endpoints (p <0.0001) in October 2024.BCC, of which sBCC is a subgroup, is the most common skin cancer in the US with more than 3 million cases each year1. WOBURN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that a key milestone in its Phase 3 study of the use of Ameluz and RhodoLED PDT in the treatment of sBCC (ALA-BCC-CT013) was met with the last patient completing the 1 year follow-up visit in December of 2024. The double-blind, randomized, placebo-controlled, multi-center study evaluated safety and efficacy in 187 patients with one or more clinically and histologically confirmed superficial BCCs. They each received one cycle of two PDT treatments (either Ameluz® -PDT or placebo-PDT) 1-2 weeks apart. Lesions that were not completely resolved after 3 months were retreated. The FDA has advised Biofrontera to submit the sNDA with one-year follow-up data. While 1-year data will support the FDA submission, the superficial BCC lesions will in total be followed up for five years. Long-term follow-up studies are often required by the FDA for dermatology product submissions, in particular for skin cancers, and they are important in trials enrolling sBCC patients due to the risk of local recurrence, or subsequent additional skin cancer development. “We were delighted with the highly statistically significant results for the primary and secondary endpoints that we communicated last year”, stated Dr Hermann Luebbert, CEO and Chairman of Biofrontera Inc. “The completion of the 1-year follow-up is a crucial milestone in our path to an FDA submission in 2025 and potentially expanding our label to the treatment of a cutaneous malignancy. It demonstrates our continued investment in PDT and supports our vision of partnering with the dermatology community to improve patient care” he concluded. “We routinely use PDT in our institution for the treatment of actinic keratoses” commented Dr Shane Chapman, Chair of the Department of Dermatology at Dartmouth Hitchcock Medical Center and the Geisel School of Medicine at Dartmouth, and an investigator for ALA-BCC-CT013. “We were impressed with the results of the 12-week data and I look forward to being able to offer Ameluz-PDT as a treatment option for my patients with sBCC”. About Basal Cell Carcinoma BCC is the most common form of skin cancer and the most frequently occurring form of all cancers. In the U.S. alone, an estimated 3.6 million cases are diagnosed each year, a subset of which is superficial basal cell carcinoma. BCCs arise from abnormal, uncontrolled growth of basal cells at the bottom of the epidermis. They rarely spread beyond the original tumor site but, if untreated, can become locally invasive, grow wide and deep into the skin, and destroy skin, tissue and bone. 1 https://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/ About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and Twitter. Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended. These statements include, but are not limited to, statements relating to the clinical development strategy for Ameluz®, ongoing clinical trials and the future impact of such trials on the market for Ameluz®, Biofrontera's commercial opportunities and the commercial success of its licensed products. We have based these forward-looking statements on our current expectations and projections about future events. Nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: the impact of any extraordinary external events; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz ® in combination with BF-RhodoLED and/or RhodoLED XL in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz in combination with BF- RhodoLED and/or RhodoLED XL is consistent with the Company’s expectations; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing; and other factors that may be disclosed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), which can be obtained on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law. Contact:Investor RelationsAndrew Barwicki1-516-662-9461ir@bfri.com

临床3期临床结果

100 项与盐酸氨酮戊酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02908	盐酸氨酮戊酸	L01XD04	DB00855

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
浸润性膀胱癌	日本	SBI Pharmaceuticals Co., Ltd.	2017-09-27
多形性胶质母细胞瘤	澳大利亚	Specialised Therapeutics Glio Pty Ltd	2013-11-07
造影剂	日本	Nobelpharma Co., Ltd.	2013-03-25
基底细胞癌	欧盟	Biofrontera Bioscience GmbH	2011-12-13
基底细胞癌	冰岛	Biofrontera Bioscience GmbH	2011-12-13
基底细胞癌	列支敦士登	Biofrontera Bioscience GmbH	2011-12-13
基底细胞癌	挪威	Biofrontera Bioscience GmbH	2011-12-13
胶质瘤	欧盟	Photonamic GmbH & Co. KG	2007-09-07
胶质瘤	冰岛	Photonamic GmbH & Co. KG	2007-09-07
胶质瘤	列支敦士登	Photonamic GmbH & Co. KG	2007-09-07
胶质瘤	挪威	Photonamic GmbH & Co. KG	2007-09-07
尖锐湿疣	中国	上海复旦张江生物医药股份有限公司	2007-02-14
光化性角化病	美国	Sun Pharmaceutical Industries, Inc.	1999-12-03

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非肌层浸润性膀胱肿瘤	临床3期	中国	上海复旦张江生物医药股份有限公司	2025-01-20
卵巢上皮癌	临床3期	美国	NX Development Corp.	2024-05-30
复发性卵巢癌	临床3期	美国	NX Development Corp.	2024-05-30
乳腺癌	临床3期	美国	Sbi Alapharma Canada, Inc.	2021-04-27
恶性上皮肿瘤	临床3期	美国	Sbi Alapharma Canada, Inc.	2021-04-27
脑膜瘤	临床3期	美国	NX Development Corp.	2020-10-28
脑膜瘤	临床3期	奥地利	NX Development Corp.	2020-10-28
脑膜瘤	临床3期	德国	NX Development Corp.	2020-10-28
浅表型基底细胞癌	临床3期	美国	Biofrontera Bioscience GmbH	2018-09-25
脑恶性胶质瘤	临床3期	日本	Nobelpharma Co., Ltd.	2010-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


TMOD-04 (SNO2024)	临床1期	-	8	Sonodynamic Therapy with 5-ALA HCL Oral Solution and CV-01	繭夢淵顧襯鬱壓製築繭(糧夢衊窪鬱廠獵淵構憲) = 蓋艱繭鬱蓋鏇遞蓋獵艱鑰憲構鏇衊衊鹽醖築鑰 (蓋觸壓艱獵鹹齋製顧鹹 )	积极	2024-11-11
				5-ALA HCL oral solution (Control Group)	繭夢淵顧襯鬱壓製築繭(糧夢衊窪鬱廠獵淵構憲) = 築淵鑰鏇獵築選積衊網鑰憲構鏇衊衊鹽醖築鑰 (蓋觸壓艱獵鹹齋製顧鹹 )
NCT01128218 (Phase 2 Sensitivity and Selectivity Study, Pubmed \| Oper Neurosurg (Hagerstown))	临床2期	复发性胶质母细胞瘤	31	High-dose 5-ALA (>40 mg/kg)	淵淵製築膚齋廠鬱觸廠(顧鹹製淵構製糧範膚範) = 糧願艱齋憲夢構廠範構築淵艱壓積膚鹽遞膚廠 (範鹽製簾齋顧齋襯蓋鏇 ) 更多	积极	2024-11-11
				Low/standard dose 5-ALA (<30 mg/kg)	淵淵製築膚齋廠鬱觸廠(顧鹹製淵構製糧範膚範) = 艱齋餘窪繭襯繭鹽艱繭築淵艱壓積膚鹽遞膚廠 (範鹽製簾齋顧齋襯蓋鏇 ) 更多
NCT03573401 (ALA-BCC-CT013, GlobeNewswire) 人工标引	临床3期	基底细胞癌	187	Ameluz®-PDT	鏇膚鏇觸鬱鏇蓋鹹糧範(鑰範鬱夢壓壓製網鹽簾) = 艱夢顧窪網鹹構醖餘鬱鑰膚鹹壓鏇衊遞壓願觸 (遞餘鏇選遞繭範範餘範 ) 更多	积极	2024-10-31
				Placebo-PDT	鏇膚鏇觸鬱鏇蓋鹹糧範(鑰範鬱夢壓壓製網鹽簾) = 窪蓋醖觸願廠鑰簾膚膚鑰膚鹹壓鏇衊遞壓願觸 (遞餘鏇選遞繭範範餘範 ) 更多
P18.53.A (EANO2024)	N/A	胶质母细胞瘤辅助 5-aminolevulinic acid (5-ALA) positive	23	5-aminolevulinic acid (5-ALA) (No residual 5-ALA)	壓壓膚積鬱壓製膚衊襯(窪襯醖製網齋構遞壓網) = 廠選鹽餘遞衊糧鏇鏇積膚餘鹹憲醖餘壓蓋鬱憲 (廠鏇願願鹹襯觸襯夢淵 ) 更多	不佳	2024-10-17
				5-aminolevulinic acid (5-ALA) (Focal residual 5-ALA)	壓壓膚積鬱壓製膚衊襯(窪襯醖製網齋構遞壓網) = 壓製願鑰窪遞製衊遞鑰膚餘鹹憲醖餘壓蓋鬱憲 (廠鏇願願鹹襯觸襯夢淵 ) 更多
P10.22.B (EANO2024)	N/A	胶质瘤	163	5-ALA (Fluorescent Gliomas)	餘齋壓艱網糧窪鬱繭艱(築遞壓獵築築夢壓窪獵) = 齋夢廠壓選繭膚窪衊顧網繭鹽顧觸網鹽艱獵艱 (繭繭築鏇蓋齋願廠繭夢 ) 更多	积极	2024-10-17
NCT03048240 (INDYGO, Pubmed \| J Neurooncol)	N/A	胶质母细胞瘤 5-aminolevulinic acid hydrochloride (5-ALA HCl)	-	Intraoperative photodynamic therapy (PDT) with 5-aminolevulinic acid hydrochloride (5-ALA HCl)	獵壓醖齋選鹽鬱製願觸(襯窪構製遞衊鬱鬱選夢) = 範壓膚簾餘鏇淵繭窪顧製簾遞簾顧顧艱顧願顧 (憲淵壓繭壓餘憲憲糧淵 ) 更多	积极	2024-07-01
NCT03327831 (CTgov)	临床4期	光化性角化病	30	Aminolevulinic Acid	繭艱選膚壓憲繭蓋範範(窪淵製襯繭壓觸蓋鏇鹽) = 鬱積遞鬱積構鬱廠獵積鑰廠遞糧獵鹽構糧齋簾 (願願廠衊夢醖簾繭壓餘, 簾窪製淵簾積鬱網壓鑰 ~ 鏇糧顧鹽鹹網鹽構窪願) 更多	-	2024-06-27
MP77-20 (AUA2024)	N/A	非肌层浸润性膀胱肿瘤	33	Fluorescence cystoscopy using oral 5-aminolevulinic acid (ALA)	廠憲夢衊範蓋顧積窪觸(構餘遞簾構獵廠窪觸餘) = 廠餘餘築製願鑰醖顧壓壓襯範夢遞膚選鏇膚齋 (醖糧鬱範獵築範醖積衊 ) 更多	积极	2024-05-01
				5-aminolevulinic acid (White-light endoscopy)	廠憲夢衊範蓋顧積窪觸(構餘遞簾構獵廠窪觸餘) = 襯積艱膚醖衊鏇構鏇齋壓襯範夢遞膚選鏇膚齋 (醖糧鬱範獵築範醖積衊 ) 更多
PD30-02 (AUA2024)	N/A	膀胱癌	302	Fluorescence cystoscopy using oral 5-aminolevulinic acid (ALA)	膚鹹網遞鹹鏇顧憲簾鑰(齋鬱衊鹹醖鹹獵鬱壓壓) = 簾鹹顧醖艱夢鬱齋蓋廠膚選夢鏇簾窪襯積襯窪 (壓鑰願鏇糧鹽廠觸簾鏇 ) 更多	不佳	2024-05-01
				5-AMINOLEVULINIC ACID (White light cystoscopy)	膚鹹網遞鹹鏇顧憲簾鑰(齋鬱衊鹹醖鹹獵鬱壓壓) = 願選觸鹹簾襯齋糧顧窪膚選夢鏇簾窪襯積襯窪 (壓鑰願鏇糧鹽廠觸簾鏇 ) 更多